Background Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined
source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation …

Survivors of stroke and transient ischaemic attacks are at risk of a recurrent stroke, which is
often more severe and disabling than the index event. Optimum secondary prevention of …

Nearly one-half of patients with cryptogenic stroke have a patent foramen ovale (PFO). The
dilemma of whether to close these PFOs percutaneously, in an effort to reduce the risk of …

Importance Recent epidemiologic and therapeutic advances have transformed
understanding of the role of and therapeutic approach to patent foramen ovale (PFO) in …

Background Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure
present in around 25% of adults. In most cases, PFO is entirely benign and requires no …

Background We conducted a systematic review and meta‐analysis of randomized controlled
trials (RCT s) comparing patent foramen ovale (PFO) closure, anticoagulation, and …

Approximately 15% of all ischemic strokes (IS) occur in young adults and adolescents. To
date, only limited prior public health and research efforts have specifically addressed stroke …

Background The comparative effectiveness of percutaneous closure of patent foramen ovale
(PFO) plus medical therapy versus medical therapy alone for cryptogenic stroke is uncertain …

Stroke is the leading cause of disability in the USA and a major cause of mortality worldwide.
One out of four strokes is recurrent. Secondary stroke prevention starts with deciphering the …

Introduction: Percutaneous closure of patent foramen ovale (PFO) in selected patients with
cryptogenic cerebrovascular ischemic events (CEs) decreases the risk of recurrent stroke; …